Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. HCW Biologics's Pre-Tax Income for the
three
months ended in Mar. 2026 was $3.80 Mil. HCW Biologics's Revenue for the
three
months ended in Mar. 2026 was $6.54 Mil. Therefore, HCW Biologics's pretax margin for the quarter that ended in Mar. 2026 was 58.12%.
The historical rank and industry rank for HCW Biologics's Pretax Margin % or its related term are showing as below:
HCWB'
s Pretax Margin % Range Over the Past 10 Years
Min: -14740.74 Med: -879.45 Max: -29.73
Current: -29.73
HCWB's Pretax Margin % is ranked better than 60.61% of 947
companies
in the Biotechnology industry
Industry Median: -90.63
vs HCWB: -29.73
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
HCW Biologics Pretax Margin % Related Terms
HCW Biologics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs MTVA, INTI, HOOK: Pretax Margin % Comparison
For the Biotechnology subindustry, HCW Biologics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Pretax Margin % of 58.12% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #373 out of 947 companies in the Biotechnology industry, placing it in the top 39.4%.
Is HCW Biologics' Pretax Margin % too high?
HCW Biologics' current Pretax Margin % is 58.12%. Based on the distribution chart, HCW Biologics ranks #373 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Pretax Margin % compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #373 out of 947 companies for Pretax Margin %. This puts HCW Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on HCW Biologics and its competitors. HCW Biologics's current Pretax Margin % is 58.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.16 — trading 84.2% below its estimated fair value. The current Pretax Margin % is 58.12%. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Pretax Margin % is 58.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.16 is trading 84.2% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Pretax Margin %: 58.12%
GF Value™: $7.29 vs. price of $1.16 (84.2% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
